Clinical trials: Primary Open-angle Glaucoma and Ocular Hypertension
- Condition Primary Open-angle Glaucoma and Ocular Hypertension
- Funder type Industry (pharma, biotech, devices)
Glaucoma, Open-Angle, Ocular Hypertension
A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
This study will evaluate the safety and efficacy of bimatoprost 0.01% in subjects with elevated intraocular pressure (IOP) due to primary open-angle glaucoma (POAG) or ocular hypertension (OH).
- Trial name
- NCT01594970
- Testing
- Bimatoprost 0.01%
- Where
- South Korea
- Volunteers
- 800 people
- Sponsor
- Allergan
Retinitis Pigmentosa, Macula Off
Transcorneal Electrical Stimulation Therapy for Retinal Disease
Transcorneal stimulation may enable neurons to survive degeneration processes via enhanced secretion of neurotrophic substances and direct stimulation of neurons.
- Conditions
- Retinitis Pigmentosa, Macula Off, Primary Open Angle Glaucoma, Hereditary Macular Degeneration
- Trial name
- NCT00804102
- Testing
- Transcorneal Electrical Stimulation, DTL-electrode attached without energy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Okuvision GmbH
Primary Open Angle Glaucoma, Ocular Hypertension
A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension
- Trial name
- NCT00595101
- Testing
- PF-03187207, Latanoprost 0.005%, PF-03187207 Vehicle
- Where
- 13 sites in Japan
- Volunteers
- 117 people
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Open-Angle, Ocular Hypertension
Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population The Zhuiguang Trial
The objective of this study is to evaluate the effectiveness (Intra-Ocular Pressure lowering) and safety of Direct Selective Laser Trabeculoplasty (DSLT) in ethnic Chinese subjects with Primary Open Angle Glaucoma or Ocular…
- Trial name
- NCT05043831
- Testing
- DSLT
- Sponsor
- BelkinVision
Primary Open Angle Glaucoma, Ocular Hypertension
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Evaluating the safety and tolerability of QLS-101 versus timolol maleate ophthalmic solution in glaucoma or ocular hypertension.
- Trial name
- NCT04830397
- Testing
- QLS-101, Timolol Maleate
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Qlaris Bio, Inc.
Glaucoma, Open-angle, Ocular Hypertension
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
This is a Phase I, multi-center, randomized, adaptive, investigator/patient-masked, placebo-controlled, parallel multiple-ascending dose study (Part A) with an extension including up to two selected doses from Part A and…
- Trial name
- NCT03293992
- Testing
- 0.01% RO7058584, 0.1% RO7058584, 1% RO7058584
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Hoffmann-La Roche
Open Angle Glaucoma
Study of ANX007 in Participants With Primary Open-angle Glaucoma
This is a double-masked, randomized, sham-controlled study evaluating two dose levels of ANX007 vs sham, administered as repeat Intravitreal (IVT) injections in patients with Primary Open-angle Glaucoma.
- Trial name
- NCT04188015
- Testing
- 2.5mg ANX007, 5.0mg ANX007
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Annexon, Inc.
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01514734
- Testing
- Brinzolamide/timolol maleate fixed combination
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- Alcon Research
Primary Open-angle Glaucoma and Ocular Hypertension
DE-117 Spectrum 5 Study
Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost low/non-responder subjects diagnosed with POAG or OHT
- Trial name
- NCT03697811
- Testing
- DE-117 Ophthalmic Solution
- Where
- 32 sites in United States
- Volunteers
- 107 people
- Sponsor
- Santen Inc.
Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.
- Conditions
- Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension (OHT)
- Trial name
- NCT06016972
- Testing
- Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Qlaris Bio, Inc.
Open Angle Glaucoma or Ocular Hypertension
OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects
It is a phase III, multi-center, randomized, single-blind (to evaluator), parallel, and positive-controlled clinical trial evaluating the efficacy and safety of OPC-1085EL in the treatment of primary open angle glaucoma or ocular…
- Trial name
- NCT05583474
- Testing
- OPC-1085EL, 0.005% Latanoprost
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Otsuka Beijing Research Institute
Primary Open-angle Glaucoma, Ocular Hypertension
A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients
TJO-002 or Acitve Control was administered on primary open-angle glaucoma or ocular hypertension patients for 12 weeks. This clinical trial study has hypothesize TJO-002 administration groups are not inferior to Active control…
- Trial name
- NCT03419975
- Testing
- TJO-002, Latanoprost
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Primary Open Angle Glaucoma of Both Eyes
Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml
The goal of this study is to compare efficacy and safety of Dorzol 20 mg/mL Eye Drops manufactured by JADRAN-GALENSKI LABORATORIJ d.d.
- Trial name
- NCT05973305
- Testing
- Dorzol 20 mg/ml, Trusopt 20 mg/ml
- Where
- Russia
- Volunteers
- 118 people
- Sponsor
- Jadran Galenski laboratorij d.d.
Glaucoma, Open-Angle, Ocular Hypertension
Corneal Versus Conjunctival Delivery Using a Delivery Device
Compare the antihypertensive efficacy of three methods for installing Xalatan
- Trial name
- NCT00143429
- Testing
- Xalatan
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-angle
Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.
This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma
- Trial name
- NCT00801437
- Testing
- Xalacom
- Where
- 39 sites in Slovakia
- Volunteers
- 457 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
To investigate safety, efficacy, and the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00868894
- Testing
- DE-104 medium concentration, DE-104 high concentration, 0.005% latanoprost
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Santen Inc.
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
Phase III trial involving topical application, in both eyes, of trabodenoson ophthalmic formulation 3.0% or 6.0% once per day or 4.5% twice per day, placebo twice per day, or timolol 0.5% twice per day for 12 weeks in adult…
- Trial name
- MATrX-1 (NCT02565173)
- Testing
- trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD
- Where
- United States
- Volunteers
- 303 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Primary Open-angle Glaucoma and Ocular Hypertension
Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6
This is a randomized, double-masked, parallel-group, multi-center study. Subjects diagnosed with POAG or OHT who meet eligibility criteria at Visit 1 (Screening) will wash out their current topical IOP lowering medication(s), if…
- Trial name
- NCT03858894
- Testing
- DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
- Where
- 13 sites in United States
- Volunteers
- 98 people
- Sponsor
- Santen Inc.
Glaucoma Open-Angle Primary, Ocular Hypertension
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
- Trial name
- NCT05913232
- Testing
- H-1337 0.6%, H-1337 1.0%, Timolol 0.5%
- Where
- 9 sites in United States
- Volunteers
- 201 people
- Sponsor
- D. Western Therapeutics Institute, Inc.
Glaucoma, Open-Angle
An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)
The purpose of this study is to evaluate the safety and effectiveness of the OMNI® Surgical System in subjects who have undergone canaloplasty and trabeculotomy using OMNI® Surgical System without any concomitant surgery in…
- Trial name
- NCT04872348
- Testing
- OMNI® Surgical System
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Sight Sciences, Inc.